title: Effect of desloratadine on patients with allergic rhinitis and exercise-induced bronchoconstriction: a placebo controlled study.
abstract: BACKGROUND
  Exercise induced broncho-constriction (EIB) is a significant problem in asthmatic patients. The link between allergic rhinitis and asthma is now well established. Patients with allergic rhinitis may have EIB.
  
  
  OBJECTIVE
  This study compared the effects of desloratadine and placebo on EIB in a group of patients with allergic rhinitis and EIB.
  
  
  METHODS
  This was a double blind placebo controlled, randomized, crossover study. Exercise challenge tests were performed before and after 7 days of treatment with either 5 mg desloratadine or placebo. Patients then underwent a washout period for 7 days and were crossed over to receive either 5mg desloratadine or placebo. The exercise challenge tests were repeated.
  
  
  RESULTS
  Desloratadine had no effect on the reduction in percentage fall in FEV(1), the AUC (0-60 min) and the time to recovery.
  
  
  CONCLUSIONS
  Desloratadine has no effect in attenuating the broncho-constriction caused by exercise in patients with allergic rhinitis and exercise induced broncho-constriction.
  
  
  CONCLUSIONS
  Patients with allergic rhinitis and exercise induced broncho-constriction must be treated with either a beta(2)-agonist or LRTA for relief or prophylaxis of their EIB.
  
  
  CONCLUSIONS
  Desloratadine does not have an effect on exercise induced bronchoconstriction. Patients with allergic rhinitis with exercise induced bronchoconstriction who are on desloratadine will still require treatment with beta(2) agonist or leukotriene receptor antagonist for their symptoms.
authors.affiliation: Paediatric Allergy and Asthma Centre, Westville Hospital, Durban, South Africa. manjra@mweb.co.za
authors.forename: A I
authors.initials: AI
authors.lastname: Manjra
authors.forename: H
authors.initials: H
authors.lastname: Nel
authors.forename: B
authors.initials: B
authors.lastname: Maharaj
mesh_terms: D000293:Adolescent; D019540:Area Under Curve; D001250:Asthma, Exercise-Induced / Q000150:complications* / Q000517:prevention & control*; D002648:Child; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D039563:Histamine H1 Antagonists, Non-Sedating / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D017336:Loratadine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D010919:Placebos; D012221:Rhinitis, Allergic, Perennial / Q000150:complications* / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D039563:Histamine H1 Antagonists, Non-Sedating; D010919:Placebos; D017336:Loratadine; C121345:desloratadine